Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglance. We place our valuation under review following this negative outcome and give a first comment.
ANNONS
Redeye comments on the disappointing news that Ascelia has received a CRL from the FDA for Orviglance. We place our valuation under review following this negative outcome and give a first comment.
